Our “off the shelf” stem cells deliver a viral payload that first kills cancer cells locally, and then supercharges the immune system to fight metastatic disease.
We are developing a new generation of targeted immunotherapies that attack solid tumors, and then teach the immune system to hunt down cancer cells elsewhere in the body.
The approach to
finding a cure is in
our name:
Tumors evade the immune system by becoming immunologically “cold”, appearing to be normal cells. From the Latin word for hot (calidus), Calidi’s platforms help the immune system recognize cancer cells, making them “hot” tumors that immune cells can then attack and destroy.
Discover the future of biotherapeutics with Calidi. Pioneering innovative solutions for solid tumors.
Discover the latest from our facility
Latest News
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine SAN DIEGO, October 22, 2025 (GLOBE…
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI)…
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference SAN DIEGO, CA., September 2, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”…
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option SAN DIEGO, CA., August 21, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE…
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering SAN DIEGO, CA., August 20, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a…
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55…
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma. SAN DIEGO, July 29, 2025…
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (“Calidi”…
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds SAN DIEGO, July 9, 2025 — Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a…
Calidi Biotherapeutics Announces Shareholder Letter from CEO
Calidi Biotherapeutics Announces Shareholder Letter from CEO SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of…